Tivic Health Systems (TIVC) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Ernst - Co-Founder, CEO & DirectorLisa Wolf - Interim CFOMichael Handley - COO & President of the Biopharma Division Operator Welcome to the Trivik Health First Quarter twenty twenty five Financial Results and Operational Update Conference Call. This call has been pre recorded and the questions you have submitted in advance will be answered following the prepared remarks. This call is being webcast and t ...

WidePoint (WYY) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jin Kang - CEO & DirectorJason Holloway - President & CRORobert George - CFO Conference Call Participants Barry Sine - AnalystScott Buck - Managing Director & Senior Technology Analyst Operator Good afternoon. Welcome to WidePoint's First Quarter twenty twenty five Earnings Conference Call. My name is Kelly, and I will be your operator for today's call. Joining us for today's presentation are WidePoint's President and CEO, J ...

Alpha Cognition (ACOG) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Henry Du - Interim CFO, VP of Finance & AccountingMichael McFadden - Director & CEOLauren D'Angelo - COORaghuram Selvaraju - Managing Director, Healthcare Equity ResearchDave Storms - Director of Equity Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Greetings, and welcome to the AlphaCognition Earnings Call. At this time, all participants are in a listen only mode ...

Financial Data and Key Metrics Changes - Revenues reached $611.1 million, representing a 7% year-over-year increase and 8.6% in constant currency, slightly below initial guidance [6][22] - Adjusted gross margin for the quarter stood at 38%, flat year-over-year, while adjusted operating margin was 14.8%, falling short of expectations due to lower revenues [24][25] - Adjusted net income for Q1 was $67.8 million, translating into an adjusted diluted EPS of $1.50, almost flat year-over-year [25][26] - Cash and cash equivalents and short-term investments were $120.2 million, with net debt at $167 million, indicating a low net debt ratio and substantial financial flexibility [25][26] Business Line Data and Key Metrics Changes - North America saw a 6% year-over-year revenue increase, Europe grew by 13.4%, and new markets experienced an 84.4% year-over-year growth, while Latin America declined by nearly 9% [22][23] - Revenue per IT head increased by 2.8% year-over-year, reflecting the value and efficiency delivered [24] Market Data and Key Metrics Changes - The macroeconomic environment has been challenging, with a significant rise in the probability of a recession in the U.S. and softening consumer spending impacting customer decisions [8][22] - Pipeline conversion has slowed, particularly in the U.S., while growth in some Latin American countries has been lower than expected [8][9] Company Strategy and Development Direction - The company is focusing on three core pillars: deepening relationships with strategic clients, expanding AI studios for comprehensive AI transformation, and implementing a subscription model for service delivery [10][12][14] - The subscription model aims to provide a flexible, consumption-based framework for clients, aligning incentives around outcomes rather than hours worked [12][14] - The company is committed to long-term value creation and transformative impact, despite current macroeconomic challenges [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength and resilience of the business, noting a robust pipeline with a 20% increase year-over-year [9][34] - The company anticipates a recovery in Latin America, with improvements noted in Argentina and Chile, although Mexico and Brazil remain challenging [36][116] - Revised revenue guidance for Q2 is at least $612 million, reflecting a cautious outlook amid macroeconomic uncertainties [26][39] Other Important Information - The company introduced Globant Coda, an AI-driven suite aimed at simplifying and accelerating the software development lifecycle [15] - Recent partnerships include a reinvention partnership with the Saudi Pro League and a collaboration with Formula One to enhance competitive experiences [17][18] Q&A Session Summary Question: Recovery of demand in Latin America - Management noted that many deals are being delayed rather than canceled, with a robust pipeline indicating potential recovery [34][36] Question: Backlog of signed contracts - The company indicated a high level of visibility and comfort regarding the backlog relative to revenue guidance, though uncertainty remains for the second half of the year [50][51] Question: Performance of top clients - Most top clients performed similarly, with stabilization expected in Q2, although those with consumer-facing exposure faced more challenges [62][64] Question: Competitive position in application development - The company maintains a balanced approach across application development, cloud, and creative services, positioning itself well in a complex market [75][76] Question: Margins in Latin America - Margins are not significantly different across regions, with a focus on maintaining healthy relationships and pricing strategies [88][90] Question: Traction of new commercial models - AI revenue is growing significantly, with the new subscription model generating early interest, although it is not yet a substantial percentage of total revenue [94][96]

Quantum Computing (QUBT) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Rosalyn Christian - Account ManagerYuping Huang - CEO & ChairmanChris Boehmler - CFO Conference Call Participants Edward Woo - Director of Research & Senior Analyst Operator Ladies and gentlemen, greetings, and welcome to the Quantum Computing Inc. First Quarter twenty twenty five Shareholder Update Call. At this time, all participants are in a listen only mode. Following management's remarks, the call will be opene ...

FitLife Brands (FTLF) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Dayton Judd - Chairman & CEOJames Bogin - Hedge Fund ManagerSamir Patel - Founder & Portfolio Manager Conference Call Participants Ryan Meyers - Senior Research AnalystSean McGowan - MD & Senior Research AnalystBill Anderson - Research Analyst Operator is now my pleasure to turn the floor over to your host, Dayton Judd, Chief Executive Officer of FitLife Brands. Sir, the floor is yours. Dayton Judd Thank you, Paul. I w ...

NRx Pharmaceuticals (NRXP) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Matthew Duffy - Chief Business Officer & Co-CEO of Hope TherapeuticsJonathan Javitt - Founder, Chairman, Chief Scientist & Co-CEO of Hope TherapeuticsMichael Abrams - CFO Conference Call Participants Thomas Shrader - MD & Healthcare AnalystEdward Woo - Director of Research & Senior Analyst Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter twenty twenty five Earning ...

Bridgeline Digital (BLIN) Q2 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Thomas Windhausen - CFO & TreasurerAri Kahn - President & CEOCasey Ryan - Director - Institutional Research Operator Please note this conference is being recorded. I will now turn the conference over to your host, Tom CFO. The floor is yours. Thomas Windhausen Excellent. Thank you. Good afternoon, everyone. Thanks for joining us today. My name is Tom Windhauser, and I'm the chief financial officer of Bridgeline Dig ...

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Cook Williams - PrincipalGregory Demopulos - Founder, Chairman, CEO & PresidentDavid Borges - VP of Finance, Chief Accounting Officer & TreasurerSteve Brozak - President & Managing PartnerNadia Dac - CCO Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer s ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [5][20] - Gross profit rose by 53% to $4,600,000, representing 58.5% of total revenue, up from 56.2% a year ago, primarily due to increased manufacturing scale and improved yield [20][21] - Net loss for Q1 2025 was $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [21][22] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA, and recurring subscribers making up 90% of revenue [6][13] - The Amazon channel represented 20% of the business, with improvements in customer conversion and repeat purchase rates [6] - The company launched new products, including a superfood tea lineup and plans for a hydration beverage, targeting significant market segments [9][12][60] Market Data and Key Metrics Changes - The company is expanding its reach into new consumer segments and channels, including international shipping and social media platforms like TikTok [42][43] - The market for non-GMO, plant-based compounds is growing, with increasing consumer awareness of health benefits related to blood flow and longevity [8][79] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025, focusing on balancing growth with profitability [17][18] - Strategic investments will be made in expanding the direct-to-consumer portfolio, enhancing R&D processes, and building AI-powered tools for CDMO services [18] - The company is targeting a 20% adjusted EBITDA margin for its direct-to-consumer division and higher margins in the CDMO segment [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its growth strategy and deliver life-changing compounds, highlighting the synergy between the direct-to-consumer and CDMO divisions [23][70] - The company is optimistic about the increasing interest from pharmaceutical companies in its botanical synthesis technology, which offers consistent and economically viable compounds [70][71] Other Important Information - The company raised $3,900,000 in debt financing during the quarter, increasing cash and cash equivalents to $3,400,000 [22] - The company is preparing to launch the olivoboscoside cell product in 2026, targeting significant market opportunities in liver health and cholesterol management [13][79] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - Management explained that Phase two involves moving from solid media to liquid media for cell conditioning, with an expected timeline of six to nine months [27][28] Question: How long will it take to narrow down targets with Tate and Lyle? - Management indicated that significant work is underway, with a comprehensive update expected by the end of the year [30] Question: Should we expect continued gross margin expansion as revenue grows? - Management affirmed the intention to drive continued gross profit margin improvement alongside revenue growth [31][32] Question: How many products contributed to revenue in Q1, and how many are expected by year-end? - Management noted that three product lines contributed to Q1 revenue, with expectations to increase to four by Q2 and five by Q3 or Q4 [36][38] Question: Will marketing costs drop due to increased ad inventory? - Management highlighted efforts to reduce marketing costs as a percentage of revenue while exploring new channels for customer acquisition [39][44] Question: Does the second quarter guidance include contributions from the CDMO business? - Management confirmed that the guidance includes revenue recognition from existing CDMO projects and potential new catalysts [45][46] Question: How many CDMO programs can be run concurrently? - Management stated that the current capacity allows for five to seven concurrent projects in stage one [49] Question: What is the long-term opportunity for the beauty product? - Management discussed a focused strategy on high-margin categories, including health and beauty, with plans for a launch in Q1 next year [60][61]